Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics CRSP revealed 11 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 54% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $330,145, and 6 were calls, valued at $617,753.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $67.5 for CRISPR Therapeutics during the past quarter.
Volume & Open Interest Trends
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for CRISPR Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CRISPR Therapeutics's whale activity within a strike price range from $30.0 to $67.5 in the last 30 days.
CRISPR Therapeutics Option Volume And Open Interest Over Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | TRADE | BULLISH | 01/17/25 | $13.6 | $13.1 | $13.6 | $55.00 | $201.2K | 529 | 0 |
| CRSP | CALL | SWEEP | NEUTRAL | 05/24/24 | $12.4 | $11.1 | $12.4 | $45.00 | $167.4K | 0 | 135 |
| CRSP | PUT | TRADE | NEUTRAL | 01/17/25 | $7.5 | $7.1 | $7.3 | $50.00 | $151.1K | 1.5K | 220 |
| CRSP | CALL | TRADE | BULLISH | 05/10/24 | $7.5 | $7.4 | $7.5 | $50.00 | $101.2K | 135 | 135 |
| CRSP | CALL | TRADE | BULLISH | 01/17/25 | $18.9 | $17.0 | $18.78 | $45.00 | $92.0K | 263 | 1 |
About CRISPR Therapeutics
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
In light of the recent options history for CRISPR Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of CRISPR Therapeutics
- With a trading volume of 673,084, the price of CRSP is down by -2.48%, reaching $56.52.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 19 days from now.
Professional Analyst Ratings for CRISPR Therapeutics
In the last month, 1 experts released ratings on this stock with an average target price of $90.0.
- An analyst from Needham downgraded its action to Buy with a price target of $90.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
